Summit Creek Advisors LLC Has $16.89 Million Stake in HealthEquity, Inc. (NASDAQ:HQY)

Summit Creek Advisors LLC reduced its position in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 7.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 254,790 shares of the company's stock after selling 21,723 shares during the period. HealthEquity makes up about 2.3% of Summit Creek Advisors LLC's portfolio, making the stock its 19th biggest holding. Summit Creek Advisors LLC owned approximately 0.30% of HealthEquity worth $16,893,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in HQY. FMR LLC raised its holdings in shares of HealthEquity by 19.1% during the 3rd quarter. FMR LLC now owns 5,648,992 shares of the company's stock worth $412,659,000 after buying an additional 907,743 shares in the last quarter. Mackenzie Financial Corp raised its holdings in shares of HealthEquity by 58.2% during the 4th quarter. Mackenzie Financial Corp now owns 1,807,407 shares of the company's stock worth $119,831,000 after buying an additional 664,979 shares in the last quarter. Invesco Ltd. raised its holdings in shares of HealthEquity by 164.6% during the 3rd quarter. Invesco Ltd. now owns 484,043 shares of the company's stock worth $35,359,000 after buying an additional 301,078 shares in the last quarter. Clearbridge Investments LLC raised its holdings in shares of HealthEquity by 12.1% during the 3rd quarter. Clearbridge Investments LLC now owns 2,204,675 shares of the company's stock worth $161,051,000 after buying an additional 238,116 shares in the last quarter. Finally, Eagle Asset Management Inc. acquired a new position in shares of HealthEquity during the 3rd quarter worth $15,581,000. 99.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HQY. KeyCorp boosted their price objective on HealthEquity from $85.00 to $95.00 and gave the stock an "overweight" rating in a research report on Friday, March 22nd. BTIG Research upped their price target on HealthEquity from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, March 20th. JPMorgan Chase & Co. upped their price target on HealthEquity from $86.00 to $108.00 and gave the company an "overweight" rating in a research report on Tuesday, April 2nd. Barclays upped their price target on HealthEquity from $84.00 to $104.00 and gave the company an "overweight" rating in a research report on Friday, February 23rd. Finally, JMP Securities began coverage on HealthEquity in a research report on Thursday, April 4th. They issued a "mkt outperform" rating and a $101.00 price target on the stock. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, HealthEquity currently has an average rating of "Moderate Buy" and a consensus target price of $96.17.

Insider Buying and Selling at HealthEquity

In other news, EVP Delano Ladd sold 2,558 shares of the company's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $82.59, for a total value of $211,265.22. Following the transaction, the executive vice president now owns 47,438 shares of the company's stock, valued at $3,917,904.42. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Evelyn S. Dilsaver sold 32,500 shares of the company's stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $79.29, for a total value of $2,576,925.00. Following the completion of the transaction, the director now directly owns 32,123 shares in the company, valued at $2,547,032.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Delano Ladd sold 2,558 shares of the firm's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $82.59, for a total value of $211,265.22. Following the transaction, the executive vice president now directly owns 47,438 shares in the company, valued at $3,917,904.42. The disclosure for this sale can be found here. Insiders sold a total of 68,823 shares of company stock valued at $5,482,975 in the last three months. Company insiders own 2.70% of the company's stock.

HealthEquity Stock Performance

HQY traded up $0.03 during trading on Monday, hitting $77.36. 361,845 shares of the company traded hands, compared to its average volume of 594,603. HealthEquity, Inc. has a one year low of $54.09 and a one year high of $84.49. The stock's fifty day moving average is $80.28 and its 200 day moving average is $74.88. The company has a quick ratio of 4.76, a current ratio of 4.76 and a debt-to-equity ratio of 0.43. The firm has a market cap of $6.64 billion, a P/E ratio of 120.88, a price-to-earnings-growth ratio of 1.26 and a beta of 0.55.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its quarterly earnings data on Tuesday, March 19th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.08. The business had revenue of $262.39 million during the quarter, compared to analyst estimates of $258.56 million. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. As a group, equities analysts predict that HealthEquity, Inc. will post 2.12 EPS for the current fiscal year.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.